



Performance Measure Review

ACP does not support QPP measure 401: "Hepatitis C: Screening for Hepatocellular Carcinoma" because the screening benefits do not outweigh the substantial risks of harms related to radiation exposure and treatment of incidental findings. Furthermore, developers cite weak evidence to form the basis of the measure. A recent evidence review demonstrates insufficient evidence for screening for hepatocellular carcinoma among patients with cirrhosis.